Live Breaking News & Updates on Adv Chronic Kidney

Stay updated with breaking news from Adv chronic kidney. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novartis iptacopan meets primary endpoint in new rare kidney disease trial

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)Ad hoc announcement pursuant to Art. 53 LRPhase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demo. ....

United States , Shreeram Aradhye , Novartis Pharmaceuticals , European Medicines Agency , Exchange Commission , Novartis Biomedical Research , Chief Medical Officer , Chinook Therapeutics , About Iga , Therapy Designation , Natl Acad , Alternative Complement Pathway With Iptacopan , Treat Iga Nephropathy , Kidney Int , Emerging Role , Complement Proteins , Rev Dis , Accessed September , Proteinuria Improves Prognosis , Practice Guideline , Current State , Clinical Trials , Parallel Group , Primary Iga Nephropathy , Clinj Am Soc , Iga Nephropathy ,

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United States , Parag Mahanti , Satoshi Sugimoto , Samir Shah , Richard Jarvis , Michael Meo , Nicole Zinsli Somm , Marlena Abdinoor , Sloan Simpson , Isabella Zinck , Julie Masow , Shreeram Aradhye , Novartis Biomedical Research , Exchange Commission , European Medicines Agency , Novartis Pharmaceuticals , Barrier Reverse , Chief Medical Officer , Chinook Therapeutics , About Iga , Therapy Designation , Natl Acad , Alternative Complement Pathway With Iptacopan , Treat Iga Nephropathy , Kidney Int , Emerging Role ,

Sonavex, Inc. awarded $1.7 Million Grant from NIH to Advance New EchoGuide Technology

Baltimore, MD (PRWEB) May 05, 2022 Sonavex, Inc., a privately held medical device company with ultrasound technologies that deliver quantitative blood flow ....

Alex Yevzlin , Johns Hopkins , Sonavex Inc , National Institute Of Diabetes , National Institutes Of Health , National Institutes , End Stage Renal Disease , Patient Care Technicians , National Institute , Kidney Diseases , Chief Medical Officer , Access Cannulation , Adv Chronic Kidney , Press Release ,

Bayer's Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

Published: May 10, 2021
May 10, 2021 11:00 UTC
Finerenone significantly reduced the risk of the composite primary endpoint of cardiovascular death and non-fatal cardiovascular events versus placebo when added to standard of care
1
FIGARO-DKD is the second positive Phase III study within the finerenone study program in CKD and T2D to meet its primary endpoint
1,2,3
Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has met its primary endpoint. The study showed finerenone significantly reduced the composite risk of time to first occurrence of cardiovascular (CV) death or non-fatal CV events (myocardial infarction, stroke, or hospitalization for heart failure). The Phase III FIGARO-DKD study included more patients with earlier stage CKD and T2D compared t ....

United States , United Kingdom , Luism Ruilope , Bayer Cross , Christian Rommel , Head Of Research , British Medical Journal Open Diabetes Research , Drug Administration , Preventative Medicine Department , International Diabetes Foundation , Public Health , Autonoma University , Kidney Fund , National Kidney Foundation , American Society Of Nephrology , International Diabetes Federation , Preventative Medicine , Executive Committee , Priority Review , American Society , Kidney Week Reimagined , New England Journal , Fast Track , Chronic Kidney Disease , Kidney Disease , Baseline Characteristics ,